Orchestra BioMed (OBIO) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
16 Jun, 2026Executive summary
Supplement provides the full text of the 2026 Employee Stock Purchase Plan (ESPP), which was omitted from the original proxy statement but previously summarized.
The ESPP aims to incentivize and retain employees by allowing them to purchase company stock, with both Section 423-compliant and non-423 components.
The plan was adopted by the board on April 22, 2026, and approved by shareholders in June 2026.
Voting matters and shareholder proposals
Shareholders were asked to approve the 2026 ESPP, which was subsequently adopted.
Board of directors and corporate governance
The board or a designated committee administers the ESPP, with authority to interpret, amend, suspend, or terminate the plan.
The board can delegate administration to committees or officers and retains final authority on policy matters.
Latest events from Orchestra BioMed
- All proposals passed, directors re-elected, and annual compensation vote frequency set.OBIO
AGM 202625 Jun 2026 - Pivotal cardiovascular device trials progress with strong partners and funding, targeting 2028 launches.OBIO
Sidoti Small-Cap Virtual Investor Conference18 Jun 2026 - Upcoming BackBeat and Virtue trial milestones signal strong growth and partnership-driven value.OBIO
Jefferies Global Healthcare Conference 20264 Jun 2026 - Pivotal cardiovascular therapies advance toward commercialization with strong partner support.OBIO
Corporate presentation4 Jun 2026 - Net loss widened to $20.7M as R&D spending rose, with cash runway into Q4 2027 and new FDA designation.OBIO
Q1 202613 May 2026 - Board recommends approval of all annual meeting proposals, including compensation and governance.OBIO
Proxy filing29 Apr 2026 - Key votes include director elections, auditor ratification, and executive pay approval.OBIO
Proxy filing29 Apr 2026 - Pivotal cardiovascular therapies advance in global trials, backed by major industry partnerships.OBIO
Corporate presentation1 Apr 2026 - Revenue up 1,539% to $33.5M; strong cash, pivotal trials advancing, more proceeds expected.OBIO
Q4 202512 Mar 2026